RxDoctor Payments Data

Paul Rodenbiker

Family · Fargo, NDNPI 1629639919

Payments from drug & device makers

$972in general payments, 2019–2025

Across 44 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$275
  • UCB, Inc.$221
  • Lundbeck LLC$99
  • Eisai Inc.$71
  • AstraZeneca$65
  • Teva Pharmaceuticals USA, Inc.$52
  • plus $189 from 9 others
$2,036in research payments, 2019–2025

Across 10 payments — averaging $203.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$972 in reported general payments places this provider in the 80th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$23,733
Medicare patients
218
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe89$66,550
Nurtec OdtRimegepant Sulfate32$37,992
LamictalLamotrigine21$22,313
QuliptaAtogepant25$21,943
TopamaxTopiramate21$18,570
Lacosamide97$18,166
Levetiracetam464$11,650
Emgality PenGalcanezumab-Gnlm14$10,418
Divalproex Sodium97$6,885
Lamotrigine211$4,438
Lamotrigine OdtLamotrigine27$4,378
Carbamazepine ErCarbamazepine52$4,239
Gabapentin253$3,953
Sumatriptan Succinate83$3,855
Propranolol Hcl ErPropranolol Hcl67$3,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Dilantin$13$40,91550 claims
AbbVieQulipta$275$21,94325 claims
Upsher-smith Laboratories LLCTopiramate$34$1,349109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 496 family providers in North Dakota.

Other family in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →